CSL Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gordon Naylor DipCompSc
- Full Time Employees
- 29,000
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 655 Elizabeth Street Melbourne VIC Australia 3000
- IPO Date
- Dec 29, 2009
- CIK
- 0001274152
- Website
- csl.com
- Similar Companies
- Business
- CSL Limited is an Australian multinational biotechnology company that researches, develops, manufactures and markets biopharmaceutical products for rare and serious diseases, influenza vaccines and iron deficiency and nephrology therapies; it operates through CSL Behring, CSL Seqirus and CSL Vifor businesses, with CSL Plasma providing plasma collection oversight. CSL Behring offers plasma-derived and recombinant therapies including immunoglobulins such as PRIVIGEN and HIZENTRA for immunodeficiencies, haemophilia treatments like HEMGENIX gene therapy, hereditary angioedema prophylaxis such as ANDEMBRY (garadacimab), Alpha-1 antitrypsin therapies, and products for neurology, cardiovascular, respiratory and transplant areas; CSL Seqirus produces influenza vaccines including FLUAD for seniors and FLUCELVAX cell-based vaccines, plus pandemic preparedness solutions; CSL Vifor provides iron deficiency treatments like Ferinject and nephrology drugs such as FILSPARI for IgAN. Founded in 1916 and headquartered in Parkville, Melbourne, Australia, the company serves patients in more than 100 countries with manufacturing sites in the US, Europe, Australia and Asia Pacific, employing over 29,000 people. Recent developments include US$1.5 billion investment in US immunoglobulin manufacturing expansion announced in November 2025, a strategic collaboration with VarmX in September 2025 featuring a $2.1 billion acquisition option for VMX-C001 to reverse anticoagulant effects, announcement of CSL Seqirus demerger in August 2025 alongside 3,000 non-US job cuts targeting $550 million annual savings, approvals and launches of ANDEMBRY in multiple markets including the US and Japan, conversion of FILSPARI conditional approval to full EU marketing authorisation in April 2025, R&D site consolidation to six global hubs, and combination of Behring and Vifor commercial functions to streamline operations.
Company News
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
Australia's CSL reports 2% fall in annual profit
CSL Q2 Earnings Beat Estimates on Record Sales, Outlook Raised
CSL to start clinical trials for new immunoglobulin manufacturing process
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations
Australia says CSL unit Seqirus to discontinue Benpen injections from November
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise
Should Value Investors Buy CSL Limited (CSLLY) Stock?
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Carlisle Companies: Resilient In Challenging Sector Backdrop
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
CSLLY or ARGX: Which Is the Better Value Stock Right Now?
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
Analyzing CSL (OTCMKTS:CSLLY) and Ascentage Pharma Group International (NASDAQ:AAPG)
CSL announces expansion of Illinois plasma therapy manufacturing facility